PDCD1 and neoplasm: Fe-EGCG@RSL3 has a tumor-control effect, and combining intravesical Fe-EGCG@RSL3 therapy with systemic anti-PD1 therapy results in better control of orthotopic bladder tumors (Fig. 6B and C).